Therapy and safety management

Joint Bone Spine

Volumn 77, Issue SUPPL. 1, 2010, Pages

  Pham, Thao ^a   Claudepierre, Pascal ^b   Constantin, Arnaud ^c   de Bandt, Michel ^d   Fautrel, Bruno ^e   Gossec, Laure ^f   Gottenberg, Jacques Eric ^g   Goupille, Philippe ^h   Guillaume, Séverine ⁱ   Hachulla, Eric ^j   Masson, Charles ^k   Morel, Jacques ^l   Puéchal, Xavier ^m   Saraux, Alain ⁿ   Schaeverbeke, Thierry ^o   Wendling, Daniel ^p   Bruckert, Eric ^e   Pol, Stanislas ^f   Mariette, Xavier ⁱ   Sibilia, Jean ^g  

^a HÔPITAL DE LA CONCEPTION   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c CHU PURPAN   (France)

^d Centre Hospitalier Robert Ballanger CHRB   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f CHU Cochin ^*  (United States)

^g HÔPITAL DE HAUTEPIERRE   (France)

^h SERVICE DE DERMATOLOGIE   (France)

ⁱ BICÊTRE HOSPITAL   (France)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k ANGERS UNIVERSITY HOSPITAL   (France)

^l LAPEYRONIE HOSPITAL   (France)

^m CENTRE HOSPITALIER DU MANS   (France)

ⁿ SERVICE DE RHUMATOLOGIE   (France)

^o HÔPITAL PELLEGRIN   (France)

^p UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALANINE AMINOTRANSFERASE; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ASPARTATE AMINOTRANSFERASE; CYCLOSPORIN; CYTOCHROME P450; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; INTERLEUKIN 6; LIVE VACCINE; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PNEUMOCOCCUS VACCINE; RITUXIMAB; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ADULT ONSET STILL DISEASE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLOIDOSIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CYTOLYSIS; DENTAL CARE; DIVERTICULITIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EMERGENCY SURGERY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNIZATION; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; LACTATION; LIVER DISEASE; LIVER FUNCTION TEST; LIVER TOXICITY; MONOTHERAPY; MOUTH HYGIENE; NEUTROPENIA; PATHOGENESIS; PHYSICAL EXAMINATION; PHYSICIAN; PREGNANCY; PRIMARY PREVENTION; RHEUMATOID ARTHRITIS; RISK FACTOR; SCREENING TEST; SECONDARY PREVENTION; SEROLOGY; SIDE EFFECT; SOLID TUMOR; SPONDYLOARTHROPATHY; THROMBOCYTOPENIA; VACCINATION; VIRUS HEPATITIS; VIRUS INFECTION; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG CONTRAINDICATION; PATIENT EDUCATION; SAFETY;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT EDUCATION AS TOPIC; RISK FACTORS; SAFETY MANAGEMENT;

EID: 77953599279     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1297-319X(10)70001-4     Document Type: Article

References (136)

1. Pham T., Fautrel B., Dernis E., et al. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with anlylosing spondylitis or psoriatic arthritis : 2007 update. Joint Bone Spine 74 6 (2007) 638-646
2. Pham T., Fautrel B., Gottenberg J.-E., et al. Rituximab (Mabthera®) therapy and safety management. Joint Bone Spine 75 Suppl.1 (2008) S1-99
3. Pham T., Claudepierre P., Constantin A., et al. Abatacept therapy and safety management. Joint Bone Spine 76 Suppl.1 (2009) S3-S5
4. Summary of Product Characteristics for tocilizumab. EMA 2009. http://www.emea.europa.eu/
5. Prise en charge thérapeutique du patient dyslipidémique. AFSSAPS 2005. http://www.afssaps.fr/Infos-de-securite/Recommandations-de-bonne-pratiqu e/Prise-encharge-du-patient-dyslipidemique/
6. Prise en charge des patients adultes atteints d'hypertension artérielle essentielle. HAS 2005. http://www.has-ante.fr/portail/upload/docs/application/pdf/hta_patient_a dulte_synthese.pdf.
7. Traitement médicamenteux du diabète de type 2 (actualisation). HAS 2006. http://www.hassante.fr/por- tail/upload/docs/application/pdf/synthese_diabete-2006.pdf.
8. Pham T., Gossec L., Constantin A., et al. Cardiovascular risk and rheumatoid arthritis: clinical practice guide- lines based on published evidence and expert opinion. Joint Bone Spine 73 (2006) 379-387
9. Méthodes d'évaluation du risque cardio-vasculaire global. ANAES 2004. http://www.hassante.fr/portail/upload/docs/application/pdf/Risque_cardo_ vasculaire_synth.pdf
10. Hippisley-Cox J., Coupland C., Vinogradova Y., et al. Predicting cardiovascular risk in England and Wales: pros- pective derivation and validation of QRISK2. BMJ 336 (2008) 1475-1482
11. van Vollenhoven R., Siri D., Furie R., et al. Long-term safety and tolerability of tocilizumab treatment in patients with rheumatoid arthritis and mean treatment duration of 2.4 years (Concurrent Abstract Session). Arthritis Rheum 60 (2009) S731 (Supplement)
12. Genovese M., Smolen J., Emery P., et al. Lipid and Inflammatory Biomarker Profiles in Patients Receiving Tocilizumab for Rheumatoid Arthritis: Analysis of Five Phase 3 Clinical Trials (Abstract). Arthritis Rheum 58 Suppl (2008) S531-S532
13. Genovese M., Smolen J., Emery P., et al. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis with Elevated Low Density Lipoprotein Cholesterol: Analysis of Five Phase 3 Clinical Trials (Abstract). Arthritis Rheum 58 Suppl (2008) S785-S786
14. Abeywardena M.Y., Leifert W.R., Warnes K.E., et al. Cardiovascular biology of interleukin-6. Curr Pharm Des 15 (2009) 1809-1821
15. Danesh J., Kaptoge S., Mann A.G., et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 5 (2008) e78
16. Montecucco F., and Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheu- matoid arthritis and atherosclerosis. Rheumatology 48 (2009) 11-22
17. Nurmohamed M.T. Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 8 (2009) 663-667
18. Aviña-Zubieta J.A., Choi H.K., Sadatsafavi M., et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59 (2008) 1690-1697
19. Boyer J.-F., Gourraud P.-A., Cantagrel A., and Constantin A. Evaluation de la prévalence des facteurs de risque cardiovasculaire classiques au cours de la polyarthrite rhumatoïde. Rev Rhum 75 (2008) 989
20. Choy E., and Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68 (2009) 460-469
21. Hahn B.H., Grossman J., Ansell B.J., et al. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 10 (2008) 213
22. Panoulas V.F., Douglas K.M., Milionis H.J., et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology 46 (2007) 1477-1482
23. John H., Hale E.D., Treharne G.J., and Kitas G.D. Patient education on cardiovascular aspects of rheumatoid disease: an unmet need. Rheumatology 46 (2007) 1513-1516
24. van Halm V.P., Peters M.J., Voskuyl A.E., et al. Rheumatoid arthritis versus diabetes as a risk factor for cardio- vascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 68 (2009) 1395-1400
25. Boyer J.F., Cantagrel A., and Constantin A. Impact of traditional therapies and biologics on cardiovascular diseases in rheumatoid arthritis. Curr Vasc Pharmacol 6 (2008) 218-227
26. Hamdulay S.S., and Mason J.C. Disease-modifying anti-rheumatic drugs: do they reduce cardiac complications of RA?. Heart 95 (2009) 1471-1472
27. Poole C.D., Conway P., and Currie C.J. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology 48 (2009) 78-82
28. Omata Y., Nakamura I., Matsui T., et al. Neutropenia induced by anti-interleukin-6 receptor antibody, tocilizumab. Ann Rheum Dis 68 Suppl3 (2009) 582
29. Nishimoto N., Yoshizaki K., Miyasaka N., et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebocontrolled trial. Arthritis Rheum 50 (2004) 1761-1769
30. Nishimoto N., Miyasaka N., Yamamoto K., et al. Long-term safety and efficacy of tocilizumab, an anti-inter- leukin-6 receptor monocolonal antibody in monotherapy, in patients with rheumatoid arthritis (the STREAM Study) : evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 68 (2009) 1580-1584
31. Maini R.N., Taylor P.C., Szechinski J., et al. Double-Blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist. Tocilizumab, in European Patients With Rheumatoid Arthritis Who Had an Incomplete Response to Methotrexate. Arthritis Rheum 54 (2006) 2817-2829
32. Smolen J.S., Beaulieu A., Rubbert-Roth A., et al. Effect of Interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebocontrolled, randomised trial. Lancet 371 (2008) 987-997
33. Nishimoto N., Miyasaka N., Yamamoto K., et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 19 (2009) 12-19
34. Nishimoto N., Hashimoto J., Miyasaka N., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray eader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 (2007) 1162-1167
35. Genovese M.C., McKay J.D., Nasonov E.L., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58 (2008) 2968-2980
36. Emery P., Keystone E., Tony H.-P., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics : results from a 24-week multicentre randomised placebo controlled trial. Ann Rheum Dis 67 (2008) 1516-1523
37. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis : the AMBITION study. Ann Rheum Dis 2009 Mars 17. (Epud ahead of print).
38. Kremer J., Fleischmann R.M., Saurigny D., et al. Safety and tolerability of tocilizumab in combination with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX : 1-year results of the LITHE study. EULAR (2009) 10-13 juin, Copenhague, Danemark. Abst. FRI0262
39. Barclay S., Pol S., Mutimer D., et al. The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting. J Clin Virol 42 (2008) 104-115
40. Van Vollenhoven RF, Keystone E, Furie R et al. Gastrointestinal safety in patients with Rheumatoid Arthritis (RA) treated with tocilizumab in the Roche clinical trials database. ACR 2009, 17-21 October, Philadelphia, Pennsylvania. Pres. 1613.
41. Loomba R., Rowley A., Wesley R., et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 148 (2008) 519-528
42. EASL clinical practical guidelines. J Hepatol 2009; 50:227-47.
43. Koike R., Harigai M., Atsumi T., et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19 (2009) 351-357
44. Kremer J, Reed G, John AK, Onofrei A. Physician behaviour in response to liver enzyme elevations in Rheumatoid Arthritis patients receiving TNF-α inhibitors and/or methotrexate : analysis of the CORRONA registry database. EULAR 2009, 10-13 June, Copenhaguen, Denmark. Abstract THU0557.
45. Kremer J., van Vollenhoven R., Ridley D.J., et al. Relationship between patient characteristics and the develop- ment of serious infections in patients receiving tocilizumab: results from long-term extension studies with a follow-up duration of 1.5 years. Arthritis Rheum 58 Suppl (2008) S-783 (Abstract 1668)
46. Fleischmann R, Burgos-Vargas R, Ambs P et al. LITHE : tocilizumab inhibits radiographic progression and improves physical fucntion in Rheumatoid Arthritis (RA) patients (Pts) at 2 Yrs with increasing clinical efficacy over time. ACR 2009, 17-21 October, Philadelphia, Pennsylvania. Pres. 637.
47. FDA. Food and Drug Administration.(http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4371s 1-02-Rochecore_files/frame.htm).
48. AFSSAPS. Prévention et prise en charge des tuberculoses survenant sous anti-TNF. http://www.agmed.sante;gouv.fr/htm/10/tnf/reco.pdf.
49. Matsui T., Komiya A., Nakayama H., et al. Neutrophil CD 64 as an infection marker for RA patients treated with tocilizumab. Ann Rheum Dis 68 suppl3 (2009) 570 (Abstract SAT 0090)
50. Gabay C. Interleukin 6 and chronic inflammation. Arthritis Res Ther 8 Suppl. 2 (2006) 53
51. Smolen J., Baulieu A.D., Dikranian A., et al. Safety of Tocilizumab in patients with rheumatoid arthritis: pooled analysis of five phase 3 clinical trials. Arthritis Rheum 58 Suppl (2008) S-784 (Abstract 1669)
52. van Vollenhoven R., Nishimoto N., Yamanaka H., et al. Experience with mycobacterium tuberculosis infection reported in the tocilizumab worldwide RA safety database. Ann Rheum Dis 68 suppl3 (2009) 567 (Abstract SAT0081)
53. Ogawa J., Harigai M., Akashi T., et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis 65 (2006) 1667-1669
54. Nagashima T., and Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology 47 (2008) 1838-1840
55. De Bandt M., and Saint-Marcoux B. Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis 68 (2009) 153-154
56. Hong D.S., Angelo L.S., and Kurzrock R. Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Cancer 110 (2007) 1911-1928
57. Mumm J.B., and Oft M. Cytokine-based transformation of immune surveillance into tumorpromoting inflammation. Oncogene 27 (2008) 5913-5919
58. Rabau M., Kashtan H., Baron S., et al. Inhibition of CT-26 murine adenocarcinoma growth in the rectum of mice treated with recombinant human interleukin-6. J Immunother Emphasis Tumor Immunol 15 (1994) 257-264
59. Bihl M., Tamm M., Nauck M., et al. Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6. Am J Respir Cell Mol Biol 19 (1998) 606-612
60. Lan Q., Zheng T., Rothman N., et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107 (2006) 4101-4108
61. Theodoropoulos G., Papaconstantinou I., Felekouras E., et al. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 12 (2006) 5037-5043
62. Heikkila K., Ebrahim S., and Lawlor D.A. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer 44 (2008) 937-945
63. Naugler W.E., Sakurai T., Kim S., et al. Gender disparity in liver cancer due to sex differences in MyD88- dependent IL-6 production. Science 317 (2007) 121-124
64. Naugler W.E., and Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14 (2008) 109-119
65. Maeda S., Kamata H., Luo J.L., et al. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005) 977-990
66. Garcia de G., Boyano D., Smith-Zubiaga I., et al. Involvement of interleukin-6 in the biology and metastatic activity of B16F10 melanoma cells. Eur Cytokine Netw 9 (1998) 187-192
67. Mouawad R., Rixe O., Meric J.B., et al. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Mol Ther 7 (2002) 151-156
68. Schuler M., Bruntsch U., Spath-Schwalbe E., et al. Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study. Eur J Cancer 34 (1998) 754-756
69. Blay J.Y., Rossi J.F., Wijdenes J., et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 72 (1997) 424-430
70. FDA. Actemra (tocilizumab) for Rheumatoid Arthritis. FDA Perspective. Arthrtis Advisory Committee, July 29 2008.
71. Laine L., Connors L.G., Reicin A., et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124 (2003) 288-292
72. Mpofu S., Mpofu C.M., Hutchinson D., et al. Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions. Ann Rheum Dis 63 (2004) 588-590
73. Hutchinson D., and Lynch M. Sigmoid diverticular abscess perforation in 2 patients with rheumatoid arthritis treated with high dose corticosteroids. A cautionary tale. J Rheumatol 28 (2001) 1935-1936
74. Durieux S., Rozenberg S., and Bourgeois P. Complications of colonic diverticular disease during rheumatoid polyarthritis: 7 cases. Rev Med Interne 20 (1999) 50-53
75. Myllykangas-Luosujärvi R., Aho K., and Isomäki H. Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died. J Rheumatol 22 (1995) 2214-2217
76. Myllykangas-Luosujärvi R. Diverticulosis - a primary cause of life-threatening complications in rheumatoid arthritis. Clin Exp Rheumatol 13 (1995) 79-82
77. Recommandations. Gastroentérol Clin Biol 31 Suppl.1 (2007) 9-22. http://www.snfge.asso.fr/01-Bibliotheque/0D-Pratiques-cliniques/reco_div erticulite-2007.pdf
78. Gallucci R.M., Sugawara T., Yucesoy B., et al. Interleukin-6 treatment augments cutaneous wound healing in immunosuppressed mice. J Interferon Cytokine Res 21 (2001) 603-609
79. Lin Z.Q., Kondo T., Ishida Y., et al. Essential involvement of Il-6 in the skin wound-healing process as evidenced by delayed wound healing in Il-6 deficient mice. J Leukoc Biol 73 (2003) 713-721
80. Hirao M., Hashimoto J., Tsuboi H., et al. Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis 68 (2009) 654-657
81. Martin C, Viviand X, Gouin F et al. Antibioprophylaxie en chirurgie. In Bergogne-Berezin E, Dellamonica P. Antibiothérapie en pratique clinique. Abrégés Masson, 2ème edition, Paris 1999.
82. Tong D.C., Rothwell B.R., et al. Antibiotic prophylaxis in dentistry: a review and practice recommendations. JADA 131 (2000) 366-374
83. CRAT : Centre de Référence sur les Agents Tératogènes, Hôpital Armand Trousseau, Paris, AP-HP. http://lecrat.org
84. Ravikumar R., Anolik J., and Looney R.J. Vaccine responses in patients with rheumatoid arthritis. Curr Rheumatol Rep 9 (2007) 407-415
85. Tsuru T., Suzaki M., Yoshio N., et al. Immune response to influenza vaccine in patients during the treatment with tocilizumab - comparison with conventional DMARDs and TNF inhibitors. Ann Rheum Dis 67 Suppl 2 (2008) 339
86. Tsuru T., Terao K., Suzaki M., et al. Immune Response to Pneumococcal Vaccine in Patients with Rheumatoid Arthritis under IL-6 Receptor Inhibition Therapy with Tocilizumab. Arthritis Rheum 56 suppl 9 (2007) S423
87. Gartlehner G., Hansen R.A., Jonas B.L., et al. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol. 27 (2008) 67-76
88. Ravelli A., and Martini A. Juvenile Idiopathic Arthritis. Lancet 369 (2007) 767-778
89. Haines K.A. Juvenile Idiopathic Arthritis Therapies in the 21st Century. Bull NYU Hosp Jt Dis. 65 (2007) 205-211
90. Oen K., Malleson P.N., Cabral D.A., et al. Disease course and outcome of juvenile rheumatoid arthritis in a multicentre cohort. J Rheumatol 29 (2002) 1989-1999
91. Recommandations HAS 2009.
92. Woo P., Wilkinson N., Prieur A.-M., et al. Open-label phase II trial of single, ascending doses of MRA in caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res & Ther. 7 (2005) R1281-R1288
93. Yokota S., Miyamae T., Imagawa T., et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52 (2005) 818-825
94. Yokota S., Imagawa T., Mori M., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371 (2008) 998-1006
95. Inaba Y., Aoki C., Ozawa R., et al. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [abstract]. Ann Rheum Dis 68 Suppl3 (2009) 720
96. Woo P., Southwood T.R., Prieur A.M., et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 43 (2000) 1849-1857
97. Laxer R.M., and Schneider R. Systemic-onset juvenile chronic arthritis. In: Isenberg D.A., Maddison P.J., Woo P., Glass D.N., and Breedveld F.C. (Eds). Oxford Textbook of Rheumatology (2004), Oxford University Press, Oxford 798-810
98. Quartier P., Taupin P., Bourdeaut F., et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48 (2003) 1093-1101
99. Gattorno M., Piccini A., Lasigliè L., et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58 (2008) 1505-1515
100. Yokota S., Miyamae T., Imagawa T., et al. Clinical study of tocilizumab in children with systemic onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 28 (2005) 231-238
101. Urakami T., Manki A., Inoue T., et al. Clinical significance of decreased serum concentration of cartilage oligomeric matrix protein in systemic juvenile idiopathic arthritis. J Rheumatol. 33 (2006) 996-1000
102. Nishimoto N., and Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2 (2006) 619-626
103. Imagawa T., Takei S., Kawano Y., et al. Efficacy and safety of tocilizumab, an anti- IL-6 receptor monoclonal antibody, in subjects with polyarticular or oligoarticular onset juvenile idiopathic arthritis [abstract]. Arthritis Rheum 54 (2006) 168
104. Aoki C., Inaba Y., Ozawa R., et al. Effects of tocilizumab on radiological findings in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis 68 Suppl3 (2009) 118
105. Okuda Y., and Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 54 (2006) 2997-3000
106. De Benedetti F., Massa M., Robbioni P., et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34 (1991) 1158-1163
107. Prieur A.M., Roux-Lombard P., and Dayer J.M. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev Rheum Engl 63 (1996) 163-170
108. De Benedetti F. Targeting interleukin-6 in pediatric rheumatic diseases. Curr Opin Rheumatol (2009) 21 DOI:10.1097/BOR.0b013e32832f1445
109. De Benedetti F., Alonzi T., Moretta A., et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I: a model for stunted growth in children with chronic inflammation. J Clin Invest 99 (1997) 643-650
110. Nakajima S., Naruto T., Miyamae T., et al. Interleukin-6 inhibits early differentiation of ATDC5 chondrogenic progenitor cells. Cytokine 47 (2009) 91-97
111. Giannini E.H., Ruperto N., Ravelli A., et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40 (1997) 1202-1209
112. de Jager W., Hoppenreijs E.P.A.H., Wulffraat N.M., et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 66 (2007) 589-598
113. Peake N.J., Khawaja K., Myers A., et al. Interleukin-6 signaling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor. Rheumatology 45 (2006) 1485-1489
114. Nishimoto N., Kanakura Y., Aozasa K., et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castelman disease. Blood 106 (2005) 2627-2632
115. Nishimoto N. Clinical studies in patients with Castleman's disease. Crohn's disease, and rheumatoid arthritis in Japan. Clin Rev Allergy Immunol. 28 (2005) 221-230
116. Kanda J., Kawakawa H., Yamaji Y., et al. Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody. Int J Hematol 85 (2007) 207-211
117. Nishimoto N., Terao K., Mima T., et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112 (2008) 3959-3964
118. Iwamoto M., Nara H., Hirata D., et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 46 (2002) 3388-3389
119. Nakahara H., Mima T., Yoshio-Hoshino N., et al. A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol 19 (2009) 69-72
120. Matsumoto K., Nagashima T., Takatori S., et al. Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab. Clin Rheumatol 28 (2009) 485-487
121. Puéchal X, De Bandt M, Berthelot JM et al. Efficacy and safety of tocilizumab in refractory adult Still's disease: a case series: submitted.
122. Scheinberg M.A., Chapira E., Fernandes M.L., and Hubscher O. Interleukin 6: a possible marker of disease activity in adult onset Still's disease. Clin Exp Rheumatol 14 (1996) 653-655
123. Hoshino T., Ohta A., Yang D., et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor- alpha levels in patients with adult Still's disease. J Rheumatol 25 (1998) 396-398
124. Fujii T., Nojima T., Yasuoka H., et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology 40 (2001) 1398-1404
125. Chen D.Y., Lan J.L., Lin F.J., and Hsieh T.Y. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 31 (2004) 2189-2198
126. Tutuncu Z.N., Bilgie A., Kennedy L.G., and Calin A. Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis. Ann Rheum Dis 53 (1994) 425-426
127. Bal A., Unlu E., Bahar G., et al. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 26 (2007) 211-215
128. Gratacós J., Collado A., Filella X., et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFNgamma) in anky- losing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33 (1994) 927-931
129. Park M.C., Lee S.W., Choi S.T., et al. Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 36 (2007) 101-106
130. Claudepierre P., Rymer J.C., Authier F.J., et al. A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies. Br J Rheumatol 36 (1997) 400-401
131. Falkenbach A., and Herold M. In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility. Rheumatol Int 18 (1998) 103-106
132. Wendling D., Racadot E., Augé B., et al. Soluble intercellular adhesion molecule 1 in spondylarthropathies. Clin Rheumatol 17 (1998) 202-204
133. Falkenbach A., Herold M., and Wigand R. Interleukin-6 serum concentration in ankylosing spondylitis: a reliable predictor of disease progression in the subsequent year?. Rheumatol Int 19 (2000) 149-151
134. François R.J., Neure L., Sieper J., and Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 65 (2006) 713-720
135. Collado-Escobar M.D., Nieto A., Matarán L., et al. Interleukin 6 gene promoter polymorphism is not associated with ankylosing spondylitis. J Rheumatol 27 (2000) 1461-1463
136. Wendling D., Racadot E., Toussirot E., and Wijdenes J. Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy. Br J Rheumatol 35 (1996) 1330